An Intrinsic Calculation For Insmed Incorporated (NASDAQ:INSM) Suggests It's 36% Undervalued
How far off is Insmed Incorporated ( NASDAQ:INSM ) from its intrinsic value? Using the most recent financial data...
Simply Wall St. · 09/10 13:18
Chief Compliance Officer Of Insmed Trades $730.57 Thousand In Company Stock
John Soriano, Chief Compliance Officer at Insmed (NASDAQ:INSM), made a large buy and sell of company shares on September 7, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission states that John Sori...
Benzinga · 09/09 23:13
Insider Sell: Insmed
MT Newswires · 09/09 16:22
Steven Cohen Boosts Health Care Exposure With Theravance Biopharma Stake
GuruFocus News · 09/08 20:55
Insmed To Participate in Five September Conferences
/PRNewswire/ -- Insmed Incorporated Inc. (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that management will participate in the following virtual investor e...
PR Newswire - PRF · 09/01 12:00
Return on Capital Employed Insights for Insmed
After pulling data from Benzinga Pro it seems like during Q2, Insmed (NASDAQ:INSM) brought in sales totaling $45.37 million. However, earnings decreased 5.65%, resulting in a loss of $88.57 million.
Benzinga · 08/27 21:14
Endurant Capital Management LP Buys Cigna Corp, Icon PLC, Thermo Fisher Scientific Inc, Sells ...
GuruFocus News · 08/27 16:38
Novo A Buys Edgewise Therapeutics Inc, Cyteir Therapeutics Inc, Bolt Biotherapeutics Inc, Sells ...
GuruFocus News · 08/18 13:38
The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 17)
Benzinga · 08/18 11:37
The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 16)
Benzinga · 08/17 12:28
Xilio Therapeutics Appoints Sara Bonstein to Its Board of Directors
Xilio Therapeutics, Inc. (Xilio), a biotechnology company developing tumor-selective immuno-oncology therapies for people living with cancer, today announced the appointment of biotech executive Sara Bonstein, chief financial officer of Insmed, Inc. (Insme...
Business Wire · 08/17 10:30
Fairmount Funds Management LLC Buys Instil Bio Inc, Zogenix Inc, Insmed Inc, Sells Mirati ...
GuruFocus News · 08/16 19:38
Stocks That Hit 52-Week Lows On Monday
  On Monday morning, 207 companies hit new 52-week lows.
Benzinga · 08/16 14:12
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
/PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the granting of inducement awards to eight new employees. In accordance w...
PR Newswire - PRF · 08/06 12:00
Insmed (INSM) Sees Hammer Chart Pattern: Time to Buy? · 08/06 11:23
Insmed Loss Widens, Revenue Higher in Q2
MT Newswires · 08/05 13:58
Insmed (INSM) Reports Q2 Loss, Tops Revenue Estimates · 08/05 13:05
BRIEF-Insmed Reports Second Quarter 2021 Financial Results And Provides Business Update · 08/05 12:01
Insmed EPS misses by $0.22, beats on revenue
Insmed (NASDAQ:INSM): Q2 GAAP EPS of -$1.07 misses by $0.22. Revenue of $45.4M (+6.8% Y/Y) beats by $1.68M. Shares +3% PM. Press Release
Seekingalpha · 08/05 11:34
HighMark Wealth Management LLC Buys Aurinia Pharmaceuticals Inc, Halozyme Therapeutics Inc, ...
GuruFocus News · 08/02 20:38
Webull provides a variety of real-time INSM stock news. You can receive the latest news about Insmed through multiple platforms. This information may help you make smarter investment decisions.
About INSM
Insmed Incorporated is a global biopharmaceutical company. The Company’s product ARIKAYCE (amikacin liposome inhalation suspension) is developed for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. The Company's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that offers a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.